Last reviewed 2026-06-03 · How we verify

Non arotinolol group

Sumitomo Pharma (Suzhou) Co., Ltd. · FDA-approved active Small molecule

Non arotinolol group is a Beta-blocker Small molecule drug developed by Sumitomo Pharma (Suzhou) Co., Ltd.. It is currently FDA-approved for Hypertension, Angina pectoris, Cardiac arrhythmias. Also known as: Control group.

Non-arotinolol group refers to beta-blockers that are structurally distinct from arotinolol, used primarily for cardiovascular conditions.

Non-arotinolol group refers to beta-blockers that are structurally distinct from arotinolol, used primarily for cardiovascular conditions. Used for Hypertension, Angina pectoris, Cardiac arrhythmias.

At a glance

Generic name	Non arotinolol group
Also known as	Control group
Sponsor	Sumitomo Pharma (Suzhou) Co., Ltd.
Drug class	Beta-blocker
Target	Beta-adrenergic receptors
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved

Mechanism of action

Beta-blockers work by antagonizing beta-adrenergic receptors, reducing heart rate and blood pressure. This class excludes arotinolol specifically, encompassing other beta-blocking agents used in hypertension and cardiac conditions. The exact mechanism depends on the specific beta-blocker within this non-arotinolol classification.

Approved indications

Hypertension
Angina pectoris
Cardiac arrhythmias

Common side effects

Fatigue
Dizziness
Bradycardia
Hypotension

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Non arotinolol group CI brief — competitive landscape report
Non arotinolol group updates RSS · CI watch RSS
Sumitomo Pharma (Suzhou) Co., Ltd. portfolio CI

Frequently asked questions about Non arotinolol group

What is Non arotinolol group?

Non arotinolol group is a Beta-blocker drug developed by Sumitomo Pharma (Suzhou) Co., Ltd., indicated for Hypertension, Angina pectoris, Cardiac arrhythmias.

How does Non arotinolol group work?

Non-arotinolol group refers to beta-blockers that are structurally distinct from arotinolol, used primarily for cardiovascular conditions.

What is Non arotinolol group used for?

Non arotinolol group is indicated for Hypertension, Angina pectoris, Cardiac arrhythmias.

Who makes Non arotinolol group?

Non arotinolol group is developed and marketed by Sumitomo Pharma (Suzhou) Co., Ltd. (see full Sumitomo Pharma (Suzhou) Co., Ltd. pipeline at /company/sumitomo-pharma-suzhou-co-ltd).

Is Non arotinolol group also known as anything else?

Non arotinolol group is also known as Control group.

What drug class is Non arotinolol group in?

Non arotinolol group belongs to the Beta-blocker class. See all Beta-blocker drugs at /class/beta-blocker.

What development phase is Non arotinolol group in?

Non arotinolol group is FDA-approved (marketed).

What are the side effects of Non arotinolol group?

Common side effects of Non arotinolol group include Fatigue, Dizziness, Bradycardia, Hypotension.

What does Non arotinolol group target?

Non arotinolol group targets Beta-adrenergic receptors and is a Beta-blocker.

Drug class: All Beta-blocker drugs
Target: All drugs targeting Beta-adrenergic receptors
Manufacturer: Sumitomo Pharma (Suzhou) Co., Ltd. — full pipeline
Therapeutic area: All drugs in Cardiovascular
Indication: Drugs for Hypertension
Indication: Drugs for Angina pectoris
Indication: Drugs for Cardiac arrhythmias
Also known as: Control group

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing